Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd VP, Marketing & Sales Hanni Neheman reported compensation-related option changes involving 15,000 options held via a trustee under the 2011 Share Award Plan. On April 7, 2026, she received several grants of employee stock options to buy 15,000 Ordinary Shares at exercise prices including $5.87 and $7.25 per share and returned matching older options with higher exercise prices of $6.12 and $7.50 to the company.
The filing notes that exercise prices, presented in U.S. dollars, were adjusted from NIS following a cash dividend declared on March 11, 2026, with no other changes to the award terms. These options vest in four equal annual installments, 25% on each anniversary of the grant date, and expire between 2028 and 2035.
Kamada Ltd. director Assaf Itshayek reported administrative option changes rather than open‑market trading. On April 7, 2026, he indirectly, through a trustee under the company’s 2011 Share Award Plan, recorded several grants of 4,000 Employee Stock Options each and matching dispositions of prior options, all over ordinary shares. The options carry exercise prices shown in U.S. dollars, converted from NIS based on the Bank of Israel rate as of April 6, 2026, and those prices were adjusted under the plan following a cash dividend declared on March 11, 2026. Each award covers options expiring on March 7, 2030 and vesting in four equal annual installments, with 25% vesting on each anniversary of the grant date.
Kamada Ltd director Leon Recanati reported a series of administrative transactions in employee stock options held indirectly through a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received multiple option grants (code A) and simultaneously returned matching options to the issuer (code D) with slightly different exercise prices.
Footnotes explain that exercise prices in U.S. dollars are convenience translations from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026, with no other changes to the awards’ terms. The options vest in four equal annual installments, and there were no open‑market purchases or sales of ordinary shares disclosed.
Kamada Ltd director Dekel Benjamin reported routine employee stock option adjustments held indirectly through a trustee under the company’s 2011 Share Award Plan. On the same date, he both received and returned options covering 4,000 ordinary shares in offsetting grant and disposition entries.
The options carry exercise prices shown in U.S. dollars as a convenience from NIS and were adjusted under the plan following a cash dividend declared on March 11, 2026. The award vests in four equal annual installments from the grant date and expires on March 7, 2030, leaving 4,000 options reported as outstanding after these transactions.
KAMADA LTD VP and General Counsel Nir Livneh reported a series of employee stock option grants and related option adjustments held via a trustee under the company’s 2011 Share Award Plan. The transactions show awards of options to buy Ordinary Shares at exercise prices stated in U.S. dollars for convenience, paired with corresponding dispositions of options back to the issuer reflecting adjusted exercise prices following a cash dividend distribution. The options vest in four equal annual installments from their grant dates and have expiration dates ranging from late 2029 to late 2035, indicating long-term, compensation-related equity exposure rather than open-market share trading.
Kamada Ltd Chief Financial Officer Chaime Orlev reported a series of administrative option adjustments under the company’s 2011 Share Award Plan. All entries relate to employee stock options held indirectly by a trustee, not to open-market share purchases or sales.
The filing shows nine grants and nine matching dispositions of options on ordinary shares, with exercise prices such as $5.87, $5.90, $6.12, $6.15, $7.25 and $7.50 per share presented in U.S. dollars. Footnotes explain that exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, and that options vest in four equal annual installments.
Kamada Ltd director and 10% owner Davidi Ishay reported multiple compensation-related option adjustments held by a trustee under the company’s 2011 Share Award Plan. The Form 4 shows paired acquisitions and dispositions of employee stock options, with 16 derivative transactions and no open‑market share purchases or sales.
The options cover blocks of 6,625 and 7,500 ordinary shares at exercise prices between $5.87 and $7.48, with expirations in 2026 and 2029. Footnotes state that exercise prices were adjusted for a cash dividend declared on March 11, 2026, and that vesting occurs in four equal annual installments from each grant date.
Kamada Ltd VP Regulatory Affairs Orit Pinchuk reported a series of employee stock option adjustments and grants held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, she was granted several blocks of 15,000 employee stock options each, with exercise prices of $5.87 and $7.25 per ordinary share and expirations extending to October 22, 2035. Matching dispositions of 15,000 options each back to the issuer at exercise prices of $6.12 and $7.50 were also reported. A footnote explains the exercise prices were adjusted under the 2011 Share Award Plan in connection with a cash dividend declared on March 11, 2026, with no other changes to the option terms, and that the options vest in four equal annual installments.
Kamada Ltd director David Tsur, through a trustee under the company’s 2011 Share Award Plan, reported a series of routine option award adjustments on Employee Stock Options (right to buy) linked to Ordinary Shares. The filing shows multiple grant acquisitions and matching dispositions back to the issuer at different exercise prices, leaving each award with 6,625 or 7,500 options outstanding per line. Exercise prices are stated in U.S. dollars as a convenience translation from NIS and were adjusted under the plan following a cash dividend declared by the board. The options vest in four equal annual installments from each grant date and carry expiration dates in 2026 and 2029.
Kamada Ltd VP of Plasma Operations Beladev Shavit reported routine employee stock option adjustments held through a trustee under the company’s 2011 Share Award Plan. The Form 4 shows five grants or awards and five matching dispositions to the issuer, each involving 15,000 options for Ordinary Shares.
Exercise prices, presented in U.S. dollars, range from $5.87 to $7.50 per share and were adjusted under the plan after a cash dividend declared on March 11, 2026. The options vest in four equal annual installments from the grant date and some series carry expiration dates as late as 2035.